InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Nasdaq: INM
Company Details
- Employees
- 17
- Address
- 815 West Hastings, St #310, Vancouver,bc V6c 1b4,canada
- Phone
- (604) 669-7207
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inmedpharma.com
- HQ
- Vancouver, BC
Inmed Pharmaceuticals Questions
Inmed Pharmaceuticals's helpline number is (604) 669-7207
Inmed Pharmaceuticals's website is http://www.inmedpharma.com
Inmed Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/inmedpharma
Inmed Pharmaceuticals has
17 employees.
View email and phone details for 17
employees at Inmed Pharmaceuticals.
Inmed Pharmaceuticals's industry is
Biotechnology Research
Inmed Pharmaceuticals's top competitors are
V-Wave,
Bicara Therapeutics,
Bridgebio,
Neuralink,
Zenas Biopharma,
Illumina Ventures,
Regeneron,
Lundbeck,
Alzamend Neuro,
Bavarian Nordic.
Inmed Pharmaceuticals's categories are Biotechnology Research
